PMC:7195088 / 20380-20899 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"670","span":{"begin":255,"end":263},"obj":"Species"},{"id":"671","span":{"begin":366,"end":376},"obj":"Species"},{"id":"792","span":{"begin":17,"end":36},"obj":"Chemical"},{"id":"793","span":{"begin":116,"end":135},"obj":"Chemical"},{"id":"794","span":{"begin":416,"end":426},"obj":"Chemical"},{"id":"795","span":{"begin":427,"end":436},"obj":"Chemical"},{"id":"934","span":{"begin":1,"end":9},"obj":"Disease"},{"id":"935","span":{"begin":208,"end":239},"obj":"Disease"},{"id":"936","span":{"begin":288,"end":296},"obj":"Disease"}],"attributes":[{"id":"A670","pred":"tao:has_database_id","subj":"670","obj":"Tax:9606"},{"id":"A671","pred":"tao:has_database_id","subj":"671","obj":"Tax:2697049"},{"id":"A792","pred":"tao:has_database_id","subj":"792","obj":"MESH:C558899"},{"id":"A793","pred":"tao:has_database_id","subj":"793","obj":"MESH:C558899"},{"id":"A794","pred":"tao:has_database_id","subj":"794","obj":"MESH:C000606551"},{"id":"A795","pred":"tao:has_database_id","subj":"795","obj":"MESH:D000241"},{"id":"A934","pred":"tao:has_database_id","subj":"934","obj":"MESH:C000657245"},{"id":"A935","pred":"tao:has_database_id","subj":"935","obj":"MESH:D007625"},{"id":"A936","pred":"tao:has_database_id","subj":"936","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":" COVID-19 and of lopinavir/ritonavir plus oseltamivir vs. darunavir/ritonavir plus oseltamivir vs. favipiravir plus lopinavir/ritonavir vs. darunavir/ritonavir plus oseltamivir plus chloroquine vs. darunavir/ritonavir plus favipiravir plus oseltamivir in patients with moderate to severe COVID-19. Open-label RCT (NCT04303299, not yet recruiting). Primary endpoint: SARS-CoV-2 eradication time (follow-up 24 weeks).\nRemdesivir Adenosine analogue. It binds to RNA-dependent RNA polymerase and acts as an RNA-chain termin"}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T13","span":{"begin":459,"end":462},"obj":"Body_part"},{"id":"T14","span":{"begin":473,"end":476},"obj":"Body_part"},{"id":"T15","span":{"begin":503,"end":506},"obj":"Body_part"}],"attributes":[{"id":"A13","pred":"fma_id","subj":"T13","obj":"http://purl.org/sig/ont/fma/fma67095"},{"id":"A14","pred":"fma_id","subj":"T14","obj":"http://purl.org/sig/ont/fma/fma67095"},{"id":"A15","pred":"fma_id","subj":"T15","obj":"http://purl.org/sig/ont/fma/fma67095"}],"text":" COVID-19 and of lopinavir/ritonavir plus oseltamivir vs. darunavir/ritonavir plus oseltamivir vs. favipiravir plus lopinavir/ritonavir vs. darunavir/ritonavir plus oseltamivir plus chloroquine vs. darunavir/ritonavir plus favipiravir plus oseltamivir in patients with moderate to severe COVID-19. Open-label RCT (NCT04303299, not yet recruiting). Primary endpoint: SARS-CoV-2 eradication time (follow-up 24 weeks).\nRemdesivir Adenosine analogue. It binds to RNA-dependent RNA polymerase and acts as an RNA-chain termin"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T99","span":{"begin":1,"end":9},"obj":"Disease"},{"id":"T100","span":{"begin":288,"end":296},"obj":"Disease"},{"id":"T101","span":{"begin":366,"end":374},"obj":"Disease"}],"attributes":[{"id":"A99","pred":"mondo_id","subj":"T99","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A100","pred":"mondo_id","subj":"T100","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A101","pred":"mondo_id","subj":"T101","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":" COVID-19 and of lopinavir/ritonavir plus oseltamivir vs. darunavir/ritonavir plus oseltamivir vs. favipiravir plus lopinavir/ritonavir vs. darunavir/ritonavir plus oseltamivir plus chloroquine vs. darunavir/ritonavir plus favipiravir plus oseltamivir in patients with moderate to severe COVID-19. Open-label RCT (NCT04303299, not yet recruiting). Primary endpoint: SARS-CoV-2 eradication time (follow-up 24 weeks).\nRemdesivir Adenosine analogue. It binds to RNA-dependent RNA polymerase and acts as an RNA-chain termin"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T103","span":{"begin":303,"end":308},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"}],"text":" COVID-19 and of lopinavir/ritonavir plus oseltamivir vs. darunavir/ritonavir plus oseltamivir vs. favipiravir plus lopinavir/ritonavir vs. darunavir/ritonavir plus oseltamivir plus chloroquine vs. darunavir/ritonavir plus favipiravir plus oseltamivir in patients with moderate to severe COVID-19. Open-label RCT (NCT04303299, not yet recruiting). Primary endpoint: SARS-CoV-2 eradication time (follow-up 24 weeks).\nRemdesivir Adenosine analogue. It binds to RNA-dependent RNA polymerase and acts as an RNA-chain termin"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T214","span":{"begin":17,"end":36},"obj":"Chemical"},{"id":"T215","span":{"begin":17,"end":26},"obj":"Chemical"},{"id":"T216","span":{"begin":27,"end":36},"obj":"Chemical"},{"id":"T217","span":{"begin":42,"end":53},"obj":"Chemical"},{"id":"T218","span":{"begin":58,"end":67},"obj":"Chemical"},{"id":"T219","span":{"begin":68,"end":77},"obj":"Chemical"},{"id":"T220","span":{"begin":83,"end":94},"obj":"Chemical"},{"id":"T221","span":{"begin":99,"end":110},"obj":"Chemical"},{"id":"T222","span":{"begin":116,"end":135},"obj":"Chemical"},{"id":"T223","span":{"begin":116,"end":125},"obj":"Chemical"},{"id":"T224","span":{"begin":126,"end":135},"obj":"Chemical"},{"id":"T225","span":{"begin":140,"end":149},"obj":"Chemical"},{"id":"T226","span":{"begin":150,"end":159},"obj":"Chemical"},{"id":"T227","span":{"begin":165,"end":176},"obj":"Chemical"},{"id":"T228","span":{"begin":182,"end":193},"obj":"Chemical"},{"id":"T229","span":{"begin":198,"end":207},"obj":"Chemical"},{"id":"T230","span":{"begin":208,"end":217},"obj":"Chemical"},{"id":"T231","span":{"begin":223,"end":234},"obj":"Chemical"},{"id":"T232","span":{"begin":240,"end":251},"obj":"Chemical"},{"id":"T233","span":{"begin":303,"end":308},"obj":"Chemical"},{"id":"T234","span":{"begin":427,"end":436},"obj":"Chemical"}],"attributes":[{"id":"A214","pred":"chebi_id","subj":"T214","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A215","pred":"chebi_id","subj":"T215","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A216","pred":"chebi_id","subj":"T216","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A217","pred":"chebi_id","subj":"T217","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A218","pred":"chebi_id","subj":"T218","obj":"http://purl.obolibrary.org/obo/CHEBI_367163"},{"id":"A219","pred":"chebi_id","subj":"T219","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A220","pred":"chebi_id","subj":"T220","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A221","pred":"chebi_id","subj":"T221","obj":"http://purl.obolibrary.org/obo/CHEBI_134722"},{"id":"A222","pred":"chebi_id","subj":"T222","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A223","pred":"chebi_id","subj":"T223","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A224","pred":"chebi_id","subj":"T224","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A225","pred":"chebi_id","subj":"T225","obj":"http://purl.obolibrary.org/obo/CHEBI_367163"},{"id":"A226","pred":"chebi_id","subj":"T226","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A227","pred":"chebi_id","subj":"T227","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A228","pred":"chebi_id","subj":"T228","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A229","pred":"chebi_id","subj":"T229","obj":"http://purl.obolibrary.org/obo/CHEBI_367163"},{"id":"A230","pred":"chebi_id","subj":"T230","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A231","pred":"chebi_id","subj":"T231","obj":"http://purl.obolibrary.org/obo/CHEBI_134722"},{"id":"A232","pred":"chebi_id","subj":"T232","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A233","pred":"chebi_id","subj":"T233","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A234","pred":"chebi_id","subj":"T234","obj":"http://purl.obolibrary.org/obo/CHEBI_16335"}],"text":" COVID-19 and of lopinavir/ritonavir plus oseltamivir vs. darunavir/ritonavir plus oseltamivir vs. favipiravir plus lopinavir/ritonavir vs. darunavir/ritonavir plus oseltamivir plus chloroquine vs. darunavir/ritonavir plus favipiravir plus oseltamivir in patients with moderate to severe COVID-19. Open-label RCT (NCT04303299, not yet recruiting). Primary endpoint: SARS-CoV-2 eradication time (follow-up 24 weeks).\nRemdesivir Adenosine analogue. It binds to RNA-dependent RNA polymerase and acts as an RNA-chain termin"}

{"project":"LitCovid-sentences","denotations":[{"id":"T142","span":{"begin":298,"end":347},"obj":"Sentence"},{"id":"T143","span":{"begin":348,"end":415},"obj":"Sentence"},{"id":"T144","span":{"begin":416,"end":446},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":" COVID-19 and of lopinavir/ritonavir plus oseltamivir vs. darunavir/ritonavir plus oseltamivir vs. favipiravir plus lopinavir/ritonavir vs. darunavir/ritonavir plus oseltamivir plus chloroquine vs. darunavir/ritonavir plus favipiravir plus oseltamivir in patients with moderate to severe COVID-19. Open-label RCT (NCT04303299, not yet recruiting). Primary endpoint: SARS-CoV-2 eradication time (follow-up 24 weeks).\nRemdesivir Adenosine analogue. It binds to RNA-dependent RNA polymerase and acts as an RNA-chain termin"}